Date: 2015-03-10
Type of information: Financing round
Company: Effimune (France)
Investors: undisclosed existing Effimune investors
Amount: € 1 million
Funding type: financing round
Planned used: These funds should enable Effimune to strengthen its capital base and accelerate the development of its product pipeline, including Effi7, an anti-IL-7 alpha receptor antibody.
Others: * On March 10, 2015, Effimune, a company specializing in the research and development of therapeutic molecules that regulate the immune system in the areas of transplantation, autoimmunity and cancer announced that the company has raised € 1,070,700, entirely from existing Effimune investors, who thus show their renewed trust in the company’s development. The total funds raised by Effimune since its creation are about 5M€, all from the same investors: founders, family funds and business angels.
Therapeutic area: Autoimmune diseases - Immunological diseases - Transplantation
